Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Toulouse – page 121

1 521 clinical trials in Toulouse, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Toulouse at a glance
1 521
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 521 trials in Toulouse

Open in trial search

Non-small cell lung cancer

Not recruiting

Study Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol Myers Squibb International Corporation

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Acute myeloid leukaemia

Not recruiting

Study on Azacitidine and Gilteritinib for Adults with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Neoplasm

Not recruiting

Study of CFT1946 alone and with trametinib or cetuximab in patients with BRAF-V600 mutant solid tumors who have received standard treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:C4 Therapeutics Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Portal hypertension

Not recruiting

Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Not recruiting

Study of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986408
  • Sponsor:Bristol Myers Squibb International Corporation

Cardiac amyloidosis

Not recruiting

Study on Long-Term Safety of Eplontersen for Adults with Transthyretin-Mediated Amyloid Cardiomyopathy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid Bp
  • Sponsor:Ionis Pharmaceuticals Inc.

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:5,7-Dimethyl-N-((1R,4R)-4-(Pentyloxy)Cyclohexyl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide
  • Sponsor:Bial R&D Investments S.A.

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Pulmonary arterial hypertension

Not recruiting

Study on the Effects of MK-5475 for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:3-(4-{(5S)-4-Amino-2-[6-Chloro-1-(3,3,4,4,4-Pentafluorobutyl)-1H-Indazol-3-Yl]-5-Methyl-6-Oxo6,7-Dihydro-5H-Pyrrolo[2,3-D]Pyrimidin-5-Yl}Phenyl)Propanoic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Toulouse

What the registry says about research in the country

01 Cardiovascular and Metabolic Research

Innovative studies focusing on heart disease treatment, including trials for TTR amyloidosis and prevention of heart failure. Advanced therapeutic approaches using novel compounds like baxdrostat in combination with established medications.

  • TTR Amyloidosis Cardiomyopathy
  • Heart Failure Prevention
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive cancer research targeting multiple types of malignancies, including head and neck cancer, gastric cancer, and advanced pancreatic cancer. Novel approaches using targeted therapies and immunotherapy combinations.

  • Head & Neck Squamous Cell Carcinoma
  • Gastric and GEJ Cancer
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
03 Neurological Disorders

Advanced research in neurodegenerative conditions and movement disorders, including studies on frontotemporal dementia, essential tremor, and traumatic brain injury outcomes.

  • Frontotemporal Dementia
  • Essential Tremor
  • Traumatic Brain Injury
  • Multiple Sclerosis
04 Autoimmune and Inflammatory Conditions

Studies investigating new treatments for inflammatory diseases, including innovative approaches for Crohn's disease, psoriatic arthritis, and myasthenia gravis.

  • Crohn's Disease
  • Psoriatic Arthritis
  • Myasthenia Gravis
  • Idiopathic Pulmonary Fibrosis
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.